Benefit of aggressive prostate CA Tx weakens as comorbidity rises

Benefit of aggressive prostate CA tx weakens as comorbidity rises

(HealthDay)—For men with early-stage prostate cancer, the cancer-specific survival benefit associated with aggressive prostate cancer treatment is reduced with increasing comorbidity, according to a study published online May 13 in Cancer.

Timothy J. Daskivich, M.D., from the University of California in Los Angeles, and colleagues compared the effectiveness of aggressive versus nonaggressive treatment for reducing cancer-specific in a cohort of 140,553 men aged ≥66 years with early-stage . Data for participants, diagnosed between 1991 and 2007, were extracted from the Surveillance, Epidemiology, and End Results-Medicare database.

The researchers found that, among men with Charlson scores of 0, 1, and 2, but not among those with scores of ≥3, aggressive treatment correlated with a reduced risk of cancer-specific mortality (subhazard ratio for Charlson score ≥3, 0.85; 95 percent confidence interval, 0.62 to 1.18) in propensity-adjusted competing-risks regression analysis. For men with Charlson scores of 0, 1, 2, and ≥3, the absolute reduction in 15-year cancer-specific mortality between men who received aggressive versus nonaggressive treatment was 6.1, 4.3, 3.9, and 0.9 percent, respectively. Aggressive treatment correlated with a lower risk of cancer-specific mortality among men who had well-differentiated and moderately-differentiated tumors with Charlson scores of 0, 1, and 2, but not ≥3 (subhazard ratio for Charlson score ≥3, 1.14; 95 percent confidence interval, 0.70 to 1.89). When considering only well- and moderately-differentiated tumors, the absolute reduction in 15-year cancer-specific mortality was 3.8, 3.0, 1.9, and −0.5 percent for men with Charlson scores of 0, 1, 2, and ≥3, respectively.

"The cancer-specific from for early-stage prostate cancer diminishes with increasing comorbidity at diagnosis," the authors write.

One author is a cofounder of Wiser Care.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Implications of very low risk prostate cancer assessed

Sep 20, 2013

(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October ...

Recommended for you

Endogenous hormones improve breast cancer risk models

22 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

22 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments